Indivior enters its third-quarter report with an unusual gap between what management says and what Wall Street models. The company's latest outlook calls for 2026 revenue of $1.295 billion to $1.365 billion, up from a prior range of $1.215 billion to $1.285 billion. The full-year consensus of roughly $1.26 billion, however, sits below even the low end of that raised range. The stock has also slid since the last report. That combination makes this print less about clearing a bar and more about proving that the bar is set too low.

For the September quarter, analysts expect earnings of $0.93 per share on revenue of $326.7 million. That would be a 29.2% jump in earnings from $0.72 a year ago, but only about 4% revenue growth from $314.0 million. It would also be a step down from the prior quarter's $1.15 and $343.0 million. A sequential decline is not unthinkable, given that management flagged gross-to-net as a headwind this year after it helped in 2025. Still, a quarter near consensus would make the upgraded annual range look ambitious. A quarter closer to the June run rate would suggest the Street is behind the curve.

The operating case rests almost entirely on Sublocade, Indivior's long-acting injectable buprenorphine. Dispense unit growth accelerated from 8% to 12% to 20% over three successive quarters. New patient starts hit a record of about 31,800 in the first quarter, up 29%, and category share held steady near 76% for six or seven quarters. Management credited its direct-to-consumer recovery campaign and favorable commercial payer mix. It raised Sublocade revenue guidance twice, to $950 million to $990 million. Adjusted EBITDA guidance also rose twice, to $620 million to $660 million. Validation this quarter means dispense growth holding in the high teens or better and share staying near the mid-70s. It also means Sublocade dollars growing fast enough to absorb pricing pressure. A sharp slowdown in volume, or evidence that gross-to-net erosion is eating more of the unit gains than expected, would challenge the story. Suboxone's continued structural decline is the other drag to monitor.

Margins matter nearly as much as the top line. The consensus implies earnings growing seven times faster than revenue, a bet that the simplification program will keep delivering. That program dropped rest-of-world operations, ended OPFI marketing and halted internal pipeline spending. First-quarter EBITDA more than doubled. The flip side is that the pipeline is now essentially empty after INDV 6001 was halted and INDV 2000 failed its Phase 2 endpoint. Some of today's leverage comes from spending that is no longer happening, so the earnings growth is real but narrower in its sources.

Overlaying everything is the all-stock merger of equals with Supernus. It is targeted to close in the fourth quarter, pending shareholder and regulatory approvals. Indivior holders would own about 56.5% of the combined company and receive a $1 billion dividend before close. The combined company is promised $125 million in annual synergies and about $2.2 billion in pro forma revenue. Any update on approvals, timing or synergy planning could move the stock as much as the quarterly numbers.

The market has not been generous. Shares have fallen 13.7% since the last report while the S&P 500 gained 2.6%. At $34.77, the stock sits below its 200-day moving average of $35.68 and in the lower part of its post-earnings range of $32.31 to $41.18. Sentiment has swung from decidedly bearish to roughly neutral, suggesting skepticism has eased rather than turned into enthusiasm. The deciding question is whether Sublocade's acceleration is durable enough to justify management's raised revenue range. If it is, the gap between guidance and consensus is an opportunity. If not, the merger may start to look like a substitute for organic momentum.